164 related articles for article (PubMed ID: 7639232)
1. Comparison of once daily doses of lansoprazole (15, 30, and 60 mg) and placebo in patients with gastric ulcer.
Avner DL; Movva R; Nelson KJ; McFarland M; Berry W; Erfling W
Am J Gastroenterol; 1995 Aug; 90(8):1289-94. PubMed ID: 7639232
[TBL] [Abstract][Full Text] [Related]
2. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Lansoprazole Study Group.
Lanza F; Goff J; Scowcroft C; Jennings D; Greski-Rose P
Am J Gastroenterol; 1994 Aug; 89(8):1191-200. PubMed ID: 8053433
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
Castell DO; Richter JE; Robinson M; Sontag SJ; Haber MM
Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693
[TBL] [Abstract][Full Text] [Related]
4. Bedtime administration of lansoprazole does not modify its greater efficacy vs ranitidine in the acute and long-term treatment of duodenal ulcer. Results from a multicentre, randomised, double blind clinical trial.
Russo A; Dattilo M
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):312-9. PubMed ID: 9476183
[TBL] [Abstract][Full Text] [Related]
5. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
[TBL] [Abstract][Full Text] [Related]
6. Comparison of once-daily doses of omeprazole (40 and 20 mg) and placebo in the treatment of benign gastric ulcer: a multicenter, randomized, double-blind study.
Valenzuela JE; Kogut DG; McCullough AJ; Colón Pagán JR; Shah U; Whipple J; Gilde LR; Simon TJ
Am J Gastroenterol; 1996 Dec; 91(12):2516-22. PubMed ID: 8946978
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled dose-ranging study of lansoprazole in the management of reflux esophagitis.
Earnest DL; Dorsch E; Jones J; Jennings DE; Greski-Rose PA
Am J Gastroenterol; 1998 Feb; 93(2):238-43. PubMed ID: 9468251
[TBL] [Abstract][Full Text] [Related]
8. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
9. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis.
Baldi F; Morselli-Labate AM; Cappiello R; Ghersi S;
Am J Gastroenterol; 2002 Jun; 97(6):1357-64. PubMed ID: 12094850
[TBL] [Abstract][Full Text] [Related]
10. Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa.
Arroyo Villarino MT; Lanas Arbeloa A; Esteva Díaz F; Ortego Fernández de Retana J; Sainz Samitier R
Rev Esp Enferm Dig; 1997 May; 89(5):347-56. PubMed ID: 9190140
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness and safety of lansoprazole in the treatment of peptic ulcer].
Ramón Nogueira J; Esquivel Ayanegui F; Esquivel Rodríguez F; Sáenz V; Santoyo R
Rev Gastroenterol Mex; 1996; 61(4):314-9. PubMed ID: 9072782
[TBL] [Abstract][Full Text] [Related]
12. Prevention of recurrence of oesophageal stricture, a comparison of lansoprazole and high-dose ranitidine.
Swarbrick ET; Gough AL; Foster CS; Christian J; Garrett AD; Langworthy CH
Eur J Gastroenterol Hepatol; 1996 May; 8(5):431-8. PubMed ID: 8804870
[TBL] [Abstract][Full Text] [Related]
13. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens.
Schwartz H; Krause R; Sahba B; Haber M; Weissfeld A; Rose P; Siepman N; Freston J
Am J Gastroenterol; 1998 Apr; 93(4):584-90. PubMed ID: 9576452
[TBL] [Abstract][Full Text] [Related]
14. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies.
Kushner PR; Snoddy AM; Gilderman L; Peura DA
Postgrad Med; 2009 Jul; 121(4):67-75. PubMed ID: 19641272
[TBL] [Abstract][Full Text] [Related]
15. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
[TBL] [Abstract][Full Text] [Related]
16. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
17. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprazole or ranitidine.
Campbell DR; Haber MM; Sheldon E; Collis C; Lukasik N; Huang B; Goldstein JL
Am J Gastroenterol; 2002 Sep; 97(9):2208-14. PubMed ID: 12358234
[TBL] [Abstract][Full Text] [Related]
18. Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.
Kovacs TO; Campbell D; Haber M; Rose P; Jennings DE; Richter J
Dig Dis Sci; 1998 Apr; 43(4):779-85. PubMed ID: 9558034
[TBL] [Abstract][Full Text] [Related]
19. [Lansoprazole--profile of a new proton pump inhibitor].
Seifert E
Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
[TBL] [Abstract][Full Text] [Related]
20. [Double-blind controlled-clinical trials of lansoprazole in the treatment of peptic ulcer].
Ogawa N
Nihon Rinsho; 1992 Jan; 50(1):68-73. PubMed ID: 1347332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
